Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.245 USD | +0.40% | +1.87% | -54.99% |
Financials (USD)
Sales 2024 * | 15.25M | Sales 2025 * | 11.36M | Capitalization | 522M |
---|---|---|---|---|---|
Net income 2024 * | -224M | Net income 2025 * | -260M | EV / Sales 2024 * | 4.16 x |
Net cash position 2024 * | 459M | Net cash position 2025 * | 228M | EV / Sales 2025 * | 25.9 x |
P/E ratio 2024 * |
-2.32
x | P/E ratio 2025 * |
-2.19
x | Employees | 255 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.7% |
Latest transcript on Verve Therapeutics, Inc.
1 day | +3.49% | ||
1 week | -2.96% | ||
Current month | +3.49% | ||
1 month | -18.16% | ||
3 months | -48.97% | ||
6 months | -33.05% | ||
Current year | -55.38% |
Managers | Title | Age | Since |
---|---|---|---|
Sekar Kathiresan
FOU | Founder | 52 | 17-12-31 |
Allison Dorval
DFI | Director of Finance/CFO | 48 | 21-11-28 |
Andrew Ashe
PSD | President | 57 | 18-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Burt Adelman
FOU | Founder | 71 | 17-12-31 |
Lonnel Coats
BRD | Director/Board Member | 58 | 22-08-07 |
Michael MacLean
BRD | Director/Board Member | 58 | 21-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.13% | 2 M€ | -25.75% | ||
3.54% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 6.26 | +0.64% | 609 683 |
24-05-13 | 6.22 | +3.49% | 1,723,340 |
24-05-10 | 6.01 | -5.50% | 1,604,714 |
24-05-09 | 6.36 | +4.61% | 1,956,209 |
24-05-08 | 6.08 | -1.30% | 1,464,270 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.38% | 522M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+42.55% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- VERV Stock